KRAS and non-small cell lung carcinoma: More information is required on the effectiveness of KRAS inhibitors for first-line treatment of metastatic (m)NSCLC; the results of several ongoing trials of KRAS inhibitors in combination with PD-(L)1 inhibitors are awaited.